633 results match your criteria Lupus Erythematosus Bullous


CAN SKIN BE A MARKER FOR INTERNAL MALIGNANCY? EVIDENCE FROM CLINICAL CASES.

Acta Clin Croat 2021 Dec;60(4):711-721

1Department of Dermatovenereology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 2School of Dental Medicine, University of Zagreb, Zagreb, Croatia; 3Unit of Dermatology and Venereology, Zabok General Hospital, Bračak/Zabok, Croatia; 4Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 5Ljudevit Jurak Department of Pathology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.

Although there are many single case reports on paraneoplastic dermatoses in the literature, there are very rare articles containing multiple cases. A retrospective study was performed to examine paraneoplastic dermatoses and accompanying malignancies based on skin manifestations and appropriate diagnostic evaluations. We recorded outcomes, current conditions, and surgical/oncologic treatments. Read More

View Article and Full-Text PDF
December 2021

Successful remission with tofacitinib in a patient with refractory bullous systemic lupus erythematosus.

Rheumatology (Oxford) 2022 May 20. Epub 2022 May 20.

Department of Rheumatology and Immunology, Peking University International Hospital, Beijing, 102206, China.

View Article and Full-Text PDF

Successful Treatment of Bullous Lupus with Corticosteroids and Belimumab: A Case Report.

Mod Rheumatol Case Rep 2022 May 11. Epub 2022 May 11.

Department of Rheumatology. Mayo Clinic Health System, Eau Claire, WI, USA.

Cutaneous lupus erythematosus (CLE) is one of the most common manifestation of systemic lupus erythematosus (SLE), although it can manifest as an independent entity as well. Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous manifestation of SLE presenting as tense vesiculobullous eruptions in a photosensitive distribution. Pathophysiology is secondary to autoantibodies against noncollagenous domain 1 and 2 (NC1 and NC2) type VII collagen and histopathology reveals dense neutrophilic infiltration of the dermis with direct immunofluorescence showing IgG deposition at dermo-epidermal junction. Read More

View Article and Full-Text PDF

The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time.

Semin Arthritis Rheum 2022 Apr 15;55:152010. Epub 2022 Apr 15.

Harvard Medical School, Massachusetts General Hospital, Boston, MA, United States.

Glucocorticoids (GCs) have been the cornerstone of treating dozens of inflammatory conditions for more than seven decades. GC toxicity is ubiquitous in both clinical trials and clinical practice, and toxicities associated with GC use are central to the experience of most patients being treated for immune-mediated conditions. These conditions span the full range of medical specialties, including rheumatology, nephrology, gastroenterology, neurology, pulmonology, ophthalmology, and others. Read More

View Article and Full-Text PDF

Oral immune-mediated disorders with malignant potential/association: An overview.

Dis Mon 2022 Mar 22:101349. Epub 2022 Mar 22.

College of Dental Medicine, Roseman University of Health Sciences, South Jordan, UT, United States. Electronic address:

A group of oral disorders or conditions, which may result from, or could be triggered by an abnormality in the normal immune response of an individual are known as oral immune-mediated disorders. Some of these disorders have malignant potential, while others are associated with malignancy. In this overview, we will discuss a few of the oral diseases (such as oral lichen planus, primary Sjogren's syndrome, systemic lupus erythematosus, dermatitis herpetiformis, and linear immunoglobulin A bullous dermatosis, to name a few), which are caused due to irregularity in the immune system and are either associated with malignancy or capable of undergoing malignant transforming, thereby increasing the morbidity and mortality rate. Read More

View Article and Full-Text PDF

Obsessive-compulsive disorder and the associated risk of autoimmune skin diseases: a nationwide population-based cohort study.

CNS Spectr 2022 Feb 11:1-7. Epub 2022 Feb 11.

School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Background: The concurrent incidence of autoimmune comorbidities in obsessive-compulsive disorder (OCD) is known. However, the association between OCD and related autoimmune skin diseases (ASDs) has not been well studied.

Objective: This study aimed to investigate the association between OCD and the risk of ASDs. Read More

View Article and Full-Text PDF
February 2022

Dermatological adverse effects of anti-glaucoma eye drops: a review.

J Eur Acad Dermatol Venereol 2022 May 11;36(5):661-670. Epub 2022 Feb 11.

Service de Dermatologie, CHRU DE NANCY Brabois, Bâtiment des Spécialités Médicales, Vandœuvre lès Nancy, France.

Many patients are treated for glaucoma. Like other drugs, anti-glaucoma eye drops may induce dermatological adverse effects. We aim to review the dermatological adverse effects secondary to the active agents in anti-glaucoma eye drops through a literature review. Read More

View Article and Full-Text PDF

Case Report: The First Reported Case of Bullous Lichen Planus-Systemic Lupus Erythematosus Overlap Syndrome.

Front Med (Lausanne) 2021 4;8:744592. Epub 2021 Nov 4.

Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Lichen planus/lupus erythematosus overlap syndrome is rarely seen in the clinic and has the characteristic clinical manifestations, histopathology, and immunopathology of lichen planus (LP) and lupus erythematosus (LE). This is the first reported case of bullous lichen planus (BLP)/systemic lupus erythematosus (SLE) overlap syndrome with hair loss as the first symptom. A 48-year-old female presented with alopecia for half a year, and skin lesions accompanied by itching on her face, trunk, and limbs for 3 months. Read More

View Article and Full-Text PDF
November 2021

A Case of Systemic Lupus Erythematosus with Cutaneous Leukocytoclastic Vasculitis Mimicking Bullous SLE.

Case Rep Dermatol 2021 Sep-Dec;13(3):464-469. Epub 2021 Sep 20.

Department of Dermatology, Nara Medical University School of Medicine, Kashihara, Japan.

Rarely, patients with systemic lupus erythematosus (SLE) develop bullous eruptions, a disease called bullous SLE in a narrow sense that has autoantibodies against type VII collagen. We describe an unusual case in which a patient with SLE developed extensive bullae on her lower extremities. Histologically, the bullous lesions were suggestive of leukocytoclastic vasculitis with deposition of C3 within blood vessel walls. Read More

View Article and Full-Text PDF
September 2021

Assessment of Clinical and Laboratory Use of the Cutaneous Direct Immunofluorescence Assay.

JAMA Dermatol 2021 Nov;157(11):1343-1348

Massachusetts General Physician Organization Dermatopathology Associates, Newton, Massachusetts.

Importance: Dermatologists submit direct immunofluorescence (DIF) biopsies on a daily basis, using an assay detecting immunoreactant deposition with a panel that has traditionally comprised immunoglobulin (Ig) G, IgA, IgM, C3, and fibrin, with or without albumin antibodies.

Objectives: To evaluate and compare the frequency of immunoreactants in DIF biopsies submitted over an 8-year period and assess use by dermatologists based on clinical impression.

Design, Setting, And Participants: A quality improvement study was conducted in a community outreach reference laboratory associated with a large academic medical center. Read More

View Article and Full-Text PDF
November 2021

Lupus erythematosus and epidermal necrolysis: a case series of 16 patients.

Br J Dermatol 2022 02 15;186(2):372-374. Epub 2021 Nov 15.

Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.

View Article and Full-Text PDF
February 2022

Bullous systemic lupus erythematosus: An uncommon manifestation in pediatric population.

Andes Pediatr 2021 Jun;92(3):428-433

Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.

Introduction: Bullous systemic lupus erythematosus (BSLE) is an autoimmune subepidermal blistering disease se condary to the presence of autoantibodies against type VII collagen of the basement membrane zone. It is considered a variant of Systemic Lupus Erythematosus (SLE) and is uncommon in the pediatric population.

Objective: To describe the case of a pediatric patient with a bullous eruption compati ble with BSLE. Read More

View Article and Full-Text PDF

A Self-Limited Facial Rash in a Lupus Patient: The Case of Primary Facial Raynaud's Phenomenon.

Case Rep Dermatol 2021 May-Aug;13(2):366-371. Epub 2021 Jul 16.

Department of Medicine, Nephrology Unit, Amiri Hospital, Ministry of Health, Kuwait City, Kuwait.

Skin is involved in 80% of systemic lupus erythematosus (SLE) and the second most affected after joint disease. Lupus-specific lesions include (a) acute ones viz. malar rash (80%), (b) subacute ones viz. Read More

View Article and Full-Text PDF

Tense blisters in a previously healthy young woman.

JAAD Case Rep 2021 Aug 24;14:108-110. Epub 2021 Jun 24.

Department of Dermatology, Medical College of Georgia at Augusta University, Augusta, Georgia.

View Article and Full-Text PDF

Cutaneous adverse events caused by immune checkpoint inhibitors.

J Am Acad Dermatol 2021 10 28;85(4):956-966. Epub 2021 Jul 28.

Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address:

Importance: Immune checkpoint inhibitors (ICIs) have emerged as active therapies for a variety of cancers. Cutaneous toxicities are common immune-related adverse events and patients will often be referred to dermatologists for evaluation.

Observations: Cutaneous adverse events to ICIs can have a variety of clinical presentations. Read More

View Article and Full-Text PDF
October 2021

Isotopic response of labetalol-associated lichen planus pemphigoides on an old radiation site: A case report.

J Cutan Pathol 2021 Dec 30;48(12):1504-1507. Epub 2021 Jul 30.

Department of Dermatology, MacKay Memorial Hospital, Taipei, Taiwan.

Over the years, the occurrences of different types of skin disorders arising from radiation sites have been observed and studied. Examples include autoimmune blistering diseases such as pemphigus, pemphigoid, and interface or inflammatory reaction patterns such as lichen planus, lupus erythematosus, and Stevens-Johnson syndrome. The phenomenon whereby a new skin disorder arises from a previously healed or irradiated site is called an isotopic response, described as a type of Koebner phenomenon. Read More

View Article and Full-Text PDF
December 2021

The epidemiology of autoimmune bullous diseases in Sudan between 2000 and 2016.

PLoS One 2021 13;16(7):e0254634. Epub 2021 Jul 13.

Faculty of Dentistry, University of Khartoum, Khartoum, Khartoum State, Sudan.

Objectives: Autoimmune bullous diseases vary in their clinico-epidemiological features and burden across populations. Data about these diseases was lacking in Sudan. We aimed to describe the epidemiological profile and to estimate the burden of autoimmune bullous diseases in Sudan. Read More

View Article and Full-Text PDF
November 2021

Thymic Stromal Lymphopoietin in Cutaneous Immune-Mediated Diseases.

Front Immunol 2021 24;12:698522. Epub 2021 Jun 24.

Department of Dermatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, Translational Medicine Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Thymic stromal lymphopoietin (TSLP) was initially demonstrated to be critical in regulating inflammatory responses among various allergic disorders (such as atopic dermatitis, food allergy, and asthma). Although two isoforms (short form and long form) of TSLP have been demonstrated in human tissues, the long form of TSLP (lfTSLP) is strongly implicated in the pathogenesis of allergies and cutaneous immune-mediated diseases. The immunomodulatory activity of lfTSLP varies widely, driving T helper (Th) cells polarizing Th2 and Th17 immune responses and inducing itch. Read More

View Article and Full-Text PDF
December 2021

Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review.

Arch Dermatol Res 2022 Aug 22;314(6):503-514. Epub 2021 Jun 22.

Department of Dermatology, Stony Brook University Hospital, Stony Brook, NY, USA.

Ustekinumab is approved for the treatment of psoriasis and Crohn's disease. Because many dermatological conditions are due to immune-mediated development, ustekinumab may be effective in other conditions. A systematic review of the off-label uses of ustekinumab, as well as on-label adverse effect, was performed, reporting on clinical improvement. Read More

View Article and Full-Text PDF

Atypical and Rare Forms of Cutaneous Lupus Erythematosus: The Importance of the Diagnosis for the Best Management of Patients.

Dermatology 2022 3;238(2):195-204. Epub 2021 Jun 3.

Section of Dermatology, Department of Health Sciences, University of Genoa, Genoa, Italy.

Lupus erythematosus (LE) is an autoimmune disease with a wide range of clinical and cutaneous manifestations. Along with the well-known typical cutaneous manifestations of LE, some cutaneous manifestations are rarer, but still characteristic, enabling the dermatologist and the general practitioner who know them to suspect cutaneous LE (CLE) and investigate a possible underlying systemic involvement. Indeed, not infrequently a skin manifestation is the first presentation of systemic LE (SLE), and >75% of SLE patients show signs of skin disease during the course of the illness. Read More

View Article and Full-Text PDF

Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review.

Drug Saf 2021 07 6;44(7):725-732. Epub 2021 May 6.

Department of Dermatology, San Gallicano Dermatological Institute-IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.

Three cyclin-dependent kinases 4/6, including palbociclib, ribociclib, and abemaciclib, have been approved for the treatment of patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer. The objective of this study was to evaluate the occurrence and clinical spectrum of cutaneous adverse events in patients with breast cancer following therapy with cyclin-dependent kinase 4/6 inhibitors. A systematic literature search was performed in the PubMed, Cochrane, and EMBASE databases up to November 2020 to evaluate studies published from 2015 to 2020. Read More

View Article and Full-Text PDF

The possible role of oral microbiome in autoimmunity.

Int J Womens Dermatol 2020 Dec 4;6(5):357-364. Epub 2020 Aug 4.

Department of Oral Medicine and Maxillofacial Pathology, School of Dentistry, Aristotle University of Thessaloniki, Greece.

Objective: The human microbiome refers to the entire habitat, including microorganisms, their genomes and the surrounding environmental conditions of the microbial ecosystem. When the equilibrium between microbial habitats and host is disturbed, dysbiosis is caused. The oral microbiome (OMB) has been implicated in the manifestation of many intra- and extraoral diseases. Read More

View Article and Full-Text PDF
December 2020

Pruritus as a Distinctive Feature of Type 2 Inflammation.

Vaccines (Basel) 2021 Mar 23;9(3). Epub 2021 Mar 23.

Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy.

Pruritus is a common symptom of several skin diseases, both inflammatory and neoplastic. Pruritus might have a tremendous impact on patients' quality of life and strongly interfere with sleep, social, and work activities. We review the role of type-2 inflammation and immunity in the pathogenesis of chronic pruritic conditions of the skin. Read More

View Article and Full-Text PDF

First description of bullous lupus associated with cutaneous leishmaniasis: coincidence or trigger?

Int J Dermatol 2021 Jul 19;60(7):896-898. Epub 2021 Mar 19.

Department of Dermatology, Centre Hospitalier de Cayenne, Cayenne, French Guiana.

View Article and Full-Text PDF

Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis.

J Am Acad Dermatol 2021 Jul 5;85(1):1-14. Epub 2021 Mar 5.

Department of Dermatology, Mayo Clinic, Rochester, Minnesota; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Subepithelial autoimmune blistering dermatoses are a group of rare skin disorders that are characterized by the disruption of the dermal-epidermal junction through the action of autoantibodies. The third article in this continuing medical education series explores the background, epidemiology, clinical features, and diagnostic criteria of each of the major subepithelial autoimmune blistering dermatoses, including bullous pemphigoid, pemphigoid gestationis, lichen planus pemphigoides, mucous membrane pemphigoid, linear IgA bullous dermatosis, and dermatitis herpetiformis. Read More

View Article and Full-Text PDF

Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy.

J Am Acad Dermatol 2021 Jul 5;85(1):18-27. Epub 2021 Mar 5.

Epiphany Dermatology, Dallas, Texas. Electronic address:

Subepidermal (subepithelial) autoimmune blistering dermatoses are a group of rare skin disorders characterized by the disruption of the dermal-epidermal junction through the action of autoantibodies. The fourth article in this continuing medical education series presents the current validated disease activity scoring systems, serologic parameters, treatments, and clinical trials for bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita, bullous systemic lupus erythematosus, anti-p200 pemphigoid, linear IgA bullous dermatosis, and dermatitis herpetiformis. Read More

View Article and Full-Text PDF

Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience.

Breast Cancer Res Treat 2021 Jul 8;188(2):535-545. Epub 2021 Mar 8.

Dermatology Department, Skin Unit, The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.

Purpose: Treatment with Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, has demonstrated significantly improved progression-free survival in patients with hormone receptor-positive, HER2-negative, advanced breast cancer, when used in combination with letrozole or fulvestrant endocrine therapies. However, limited information exists on its cutaneous adverse effects (AE). Hence, we conducted a retrospective cohort study to investigate the prevalence and management of cutaneous AE during palbociclib and endocrine therapy. Read More

View Article and Full-Text PDF

An atypical case of pediatric epidermolysis bullosa acquisita: Review of diagnosis and pitfalls.

JAAD Case Rep 2021 Mar 20;9:81-85. Epub 2021 Jan 20.

Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin.

View Article and Full-Text PDF

Patchy Alopecia in a Patient with Rheumatoid Arthritis: A Practical Application of Trichoscopy.

Case Rep Dermatol 2021 Jan-Apr;13(1):42-46. Epub 2021 Jan 25.

Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Razi Hospital, Tehran, Iran.

Trichoscopy is an efficient, convenient, and accurate diagnostic dermatological procedure which is widely used in the examination of patients with skin diseases. Herein, we report a 56-year-old woman with a long-term history of rheumatoid arthritis complaining of pruritic patchy alopecia on her scalp who was referred for biopsy to exclude cutaneous lupus erythematosus. Taking advantage of trichoscopy, we were able to quickly diagnose tinea capitis. Read More

View Article and Full-Text PDF
January 2021

Pemphigus erythematosus: A case series from a tertiary academic center and literature review.

J Cutan Pathol 2021 Aug 9;48(8):1038-1050. Epub 2021 Mar 9.

Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.

Background: Pemphigus erythematosus (PE) is a rare autoimmune skin condition with clinical, histopathological, and serological features that show overlap between lupus erythematosus and pemphigus foliaceus. It typically presents with erythematous, scaly plaques and has a female predominance.

Methods: After Institutional Review Board (IRB) approval, we searched the internal pathology database for "pemphigus erythematosus" in the diagnostic line between 1 January 2000 and 30 July 2020. Read More

View Article and Full-Text PDF